FDA approved Valeant's Siliq to treat adults with moderate-to-severe plaque psoriasis, in which patients develop thick, red skin with flaky, silver-white scales, is the most common form of the disease.
A patient's body coverage is measured and if above 10% the biologic prescription is processed for approval with our on-site coordinator, Sue Lamb. One needs to be checked and cleared for TB with our on-site test and return three days later for a reading to identify a smooth surface by our medical staff. A before and after picture will be taken and any marking beyond clear will require the provider to be notiified for final measurement of area before a biologic can be administered.
Siliq is noted to be forewarned of suicidal behavior by the FDA labeling. All IDT psoriasis patients' are placed in prescription program and monitored to provide top-notch safety, alongside a 3-month evaluation with Dr. Schreiber.